Recommended dose: Adults: Hypertension: Usual dosage: 80 to 320 mg once daily.
Maximum dose: 320 mg/day.
Initial dosage: 80 or 160 mg once daily when used as monotherapy in patients who are not volume depleted. Patients requiring greater reductions may be started at a higher dose.
Dosage adjustment: If additional antihypertensive effect is required, the dose may be increased to a maximum of 320 mg/day, or a diuretic may be added.
Heart failure: Maximum dose: 320 mg/day.
Initial dosage: 40 mg twice daily.
Dosage titration: Up titration to 80 and 160 mg twice daily should be done to the highest dose as tolerated by the patient.
Concomitant therapy: Consider reducing the dose of concomitant diuretics.
Post-myocardial infarction: Initial dosage: 20 mg twice daily initiated as early as 12 hours after an MI.
Dosage titration: Patients may be up-titrated within 7 days to 40 mg twice daily, with subsequent titrations to a target maintenance dosage of 160 mg twice daily, as tolerated by the patient. If symptomatic hypotension or renal function impairment occurs, consider a dosage reduction.
Concomitant therapy: Valsartan may be given with other standard post-MI treatments, including thrombolytics, aspirin, beta-blockers, and statins.
Children 6 to 16 years of age: Hypertension: Initial dosage: 1.3 mg/kg once daily (up to 40 mg total).
Dosage adjustment: Adjust dosage according to blood pressure response. Dosages higher than 2.7 mg/kg (up to 160 mg) once daily have not been studied.
Elderly: Modification of valsartan dosage is not necessary for elderly patients.
Renal function impairment: Modification of valsartan dosage is not necessary for patients with mild to moderate renal impairment. Valsartan has not been studied in patients with creatinine clearances (CrCl) of less than 10 mL/minute and should be used with caution in adults with severe renal impairment.
Hepatic function impairment: Modification of valsartan dosage is not necessary for patients with mild to moderate chronic liver disease. Valsartan should be used with caution in patients with hepatic impairment.
Mode of administration: Valsartan GPO tablet is administered orally and may be administered with or without food.